LIB Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Lerodalcibep(Lerochol)
Phase 3
PCSK9Protein / enzyme therapeutic
Atherosclerotic Cardiovascular Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
Lerodalcibep · LerocholPhase 3Familial Hypercholesterolemia - Heterozygous
Est. primary completion 2028-07-31 · NCT07102511 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Lerodalcibep · LerocholPhase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2031-07-31 · NCT07775339 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2026Filing acceptedLerodalcibepNMPA accepts the LEROCHOL (lerodalcibep) BLA for hypercholesterolemia
CN, NMPA · Everest Medicines · Source ↗

Financial reports

No financial reports recorded.